Seneste opdatering :
22/01/2021
Infostab
Lister
Bversigter
Søg efter uforeneligheder
Tabel over uforenelighed
Bibliografi
Forskerhold
Poster
Links
Forfatter
Brugervejledning
Nyhedsbrev
Bibliografi 4433
Type :
Journal
Internet-link :
https://doi.org/10.1016/j.clinthera.2020.01.017
Forskerhold :
Philadelphie - Philadelphia College of Pharmacy and Science
Forfattere :
Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K.
Titel :
Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications
Nummer :
Clin Ther ; 42, 3: 475-485. 2020
Cotationvaleur :
Fysisk stabilitet :
Kemisk stabilitet :
Andre metoder :
Kommentarer :
Lister
Dexamethasone sodium phosphate
1 mg/ml
+
Imipenem-Cilastatin / Relebactam
5 mg/ml
+
Furosemide
10 mg/ml
+
Imipenem-Cilastatin / Relebactam
5 mg/ml
+
Haloperidol lactate
5 mg/ml
+
Imipenem-Cilastatin / Relebactam
5 mg/ml
+
Hydrocortisone sodium succinate
1 mg/ml
+
Imipenem-Cilastatin / Relebactam
5 mg/ml
+
Imipenem-Cilastatin / Relebactam
5 mg/ml
+
Dexamethasone sodium phosphate
1 mg/ml
+
5 mg/ml
+
Furosemide
10 mg/ml
+
5 mg/ml
+
Haloperidol lactate
5 mg/ml
+
5 mg/ml
+
Hydrocortisone sodium succinate
1 mg/ml
+
5 mg/ml
+
Insulin glulisine
1 U/ml
+
5 mg/ml
+
Labetalol hydrochloride
2 mg/ml
+
5 mg/ml
+
Phenytoin sodium
5 mg/ml
+
Insulin glulisine
1 U/ml
+
Imipenem-Cilastatin / Relebactam
5 mg/ml
+
Labetalol hydrochloride
2 mg/ml
+
Imipenem-Cilastatin / Relebactam
5 mg/ml
+
Phenytoin sodium
5 mg/ml
+
Imipenem-Cilastatin / Relebactam
5 mg/ml
+
Mentions Légales